For instance, the approved immune checkpoint blockade drugs which target cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) or its ligand, programmed cell death ligand 1 (PD-L1), have shown efficacy in prolonging the overall survival of patients with various cancers. Here, PDCD1 is linked to cancer.